Redx Pharma plc Change of Auditor (7874A)
June 04 2021 - 2:00AM
UK Regulatory
TIDMREDX
RNS Number : 7874A
Redx Pharma plc
04 June 2021
REDX PHARMA PLC
("Redx" or "the Company")
Change of Auditor
Alderley Park, 4 June 2021, Redx Pharma plc (AIM: REDX), the
drug discovery and development company focused on cancer and
fibrosis, announces the appointment of Ernst & Young LLP ('EY')
as the Company's auditor for the financial year ending 30 September
2021 following the conclusion of a competitive tender process led
by the Company's Audit Committee. The appointment of EY for the
subsequent financial year will be subject to approval by the
Company's shareholders at the next Annual General Meeting to be
held in 2022.
RSM UK Audit LLP ("RSM"), have consequently resigned as
auditors. RSM has confirmed to the Company that there are no
circumstances connected with its resignation which it considers
should be brought to the attention of the members or creditors of
the Company.
The Company would like to thank RSM for their support over the
last six years.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469 918
Peter Presland, Interim Chairman
Lisa Anson, Chief Executive
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368 3550
Matt Davis/Adam Dawes
WG Partners LLP (Joint Broker) T: +44 20 3705 9330
Claes Spång/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 20 7886 2500
Rupert Dearden/Freddy Crossley/Emma Earl
FTI Consulting T: +44 20 3727 1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic diseases, aiming initially to progress them to
clinical proof of concept, before evaluating options for further
development and potential value creation. Redx's lead oncology
asset, RXC004, is currently in a Phase 1 study in patients with
advanced malignancies and Redx intends to report the Phase 1
clinical study results at a scientific meeting, as well as initiate
multiple Phase 2 studies in H2 2021. The Company's selective ROCK2
inhibitor, RXC007, is in development for idiopathic pulmonary
fibrosis and commenced a Phase 1 clinical study in June 2021 for
which results are expected in 2022.
The Company has a strong track record of discovering new drug
candidates through its core capability of converting medicinal
chemistry insights into differentiated and commercially attractive
drug candidates, and has previously completed preclinical asset
transactions with Loxo Oncology (now Eli Lilly), AstraZeneca and
Jazz Pharmaceuticals.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPDKNBQPBKDQAK
(END) Dow Jones Newswires
June 04, 2021 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Jul 2023 to Jul 2024